Designer virus acts as a molecular-level switch
The ability to switch disease-causing genes on and off remains a dream for many physicians, research scientists and patients. Research teams from across the world are busy turning this dream into a reality, including a team of researchers from Charité – Universitätsmedizin Berlin and the Max Planck Institute for Medical Research in Heidelberg. Led by Dr. Mazahir T. Hasan, and working under the auspices of the NeuroCure Cluster of Excellence, the team has successfully programmed a virus to transport the necessary genetic material to affected tissue and nerve cells inside the body. A report on their new virus-based method, which delivers instructions to the host genome without becoming part of it, has been published in the journal Molecular Therapy Nucleic Acids*.
From cancer to Alzheimer’s disease, many life-threatening diseases can only be treated using drug-based treatment options, if at all. Many of these treatments are non-specific in nature, or even ineffective. In some cases, the undesirable side-effects may even outweigh the desirable ones. This is because indiscriminate treatments damage healthy cells, impairing their ability to communicate with other cells; as a result, it is hoped that genetically produced and modified mediators will be able to selectively target diseased cells, and improve the way treatment is delivered. “In the laboratory, we use attenuated, i.e. non-replicating,viruses that are known as recombinant adeno-associated viruses (rAAV). We use them to transport genetically encoded material into live organisms affected by disease,” explains Dr. Hasan. “This approach opens up a whole range of options which, in the future, may allow us to treat and heal various diseases.”
By successfully completing the initial step of testing this new method using an animal model, the researchers have laid the groundwork for future genetic treatments for use in humans. Before these can be used, however, they will need to be tested to ensure their safety. It is already known that rAAVs can transport genetically encoded material into any type of cell and tissue, including the brain, and that, once inside the cells, they are capable of repeatedly switching gene therapy applications on and off again. This on/off switch is controlled chemically, via either food intake or drinking water: “The fact that gene function can be switched on and off in this manner is of particular value, and renders the method a perfect candidate for use in controlled gene therapy,” emphasizes Dr. Hasan
A discovery by Washington State University scientist Dan Rodgers and collaborator Paul Gregorevic could save millions of people suffering from muscle wasting disease.
The result of the team’s four-year project is a novel gene therapeutic approach. The work was published (http://stm.sciencemag.org/content/8/348/348ra98) July 20 in Science Translational Medicine, a journal of the American Association for the Advancement of Science.
“Chronic disease affects more than half of the world’s population,” said Rodgers, professor of animal sciences (https://ansci.wsu.edu/people/faculty/dan-rodgers/) and director of the Washington Center for Muscle Biology (http://wcmb.wsu.edu/). “Most of those diseases are accompanied by muscle wasting.
“It occurs with chronic infection, muscular dystrophy, malnutrition and old age,” he said. “About half the people who die from cancer are actually dying from muscle wasting and there’s not one single therapy out there that addresses it.
Family history inspires search for treatment
“I have a strong motivation to do something about this, to do more than simply publish results,” said Rodgers, who teamed with Gregorevic of Baker IDI Heart and Diabetes Institute in Australia (https://www.bakeridi.edu.au/). “My father died from cachexia,” the wasting disease caused by cancer, “and my nephew has Duchenne muscular dystrophy, an incurable, fatal disease that could claim his life in his teens.
Deep learning has already had a huge impact on computer vision and speech recognition, and it’s making inroads in areas as computer-unfriendly as cooking. Now a new startup led by University of Toronto professor Brendan Frey wants to cause similar reverberations in genomic medicine.
Deep Genomics plans to identify gene variants and mutations never before observed or studied and find how these link to various diseases. And through this work the company believes it can help usher in a new era of personalized medicine.
Genomic research is hard. Scientists still know relatively little about our genes and how they interrelate. But Frey and others in the field now know enough that they can equip machines to do the heavy lifting. And there’s an awful lot of this heavy lifting to do. “Genomics is no longer about small datasets,” Frey tells Gizmag. “It’s now about very, very large datasets.”
For context, the first effort to sequence a full human genome took 13 years – running from 1990 to 2003. There are now many companies working to sequence many genomes at a time. The largest of these is called Illumina. “Illumina,” Frey says, “expects to sequence one million genomes in the next year. Each genome contains three billion letters. That’s a lot of data.”